<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="687">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355338</url>
  </required_header>
  <id_info>
    <org_study_id>COV-01-IB</org_study_id>
    <nct_id>NCT04355338</nct_id>
  </id_info>
  <brief_title>Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)</brief_title>
  <acronym>AVISA</acronym>
  <official_title>Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study, meaning that no interventions is tested, to determine&#xD;
      incidence of SARS-CoV-2 infection and COVID-19 in different clinical sites in Brazil in&#xD;
      several age groups. The study aims to assess baseline number of infected participants and&#xD;
      perform a follow-up along two years to determine the new cases occurring among participants&#xD;
      during the period. All participants will collect blood samples to get more details on the&#xD;
      immune response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational longitudinal study to assess incidence of SARS-CoV-2 infection in&#xD;
      Brazil. The study sample is stratified in nine age groups according decades of life, equally&#xD;
      distributed in both sexes, with an expected incidence of 10%, at least, during the study&#xD;
      period of 24 months. For the first age groups, (0-9, 10-19 and 20-29 years), sample was&#xD;
      calculated with the minimum expected incidence of COVID-19 among infected, regardless&#xD;
      severity, is 10%. For the latest age groups (30-39, 40-49, 50-59, 60-69, 70-79 and 80+), the&#xD;
      sample was calculated with the expected minimum incidence of hospitalization due to COVID-19&#xD;
      according to estimates per age group reported by Verity R et al.&#xD;
      https://doi.org/10.1016/S1473-3099(20)30243-7 After the consent procedure, all participants&#xD;
      will have a short interview, a IgG/IgM SARS-CoV-2 rapid test and a blood withdrawal to obtain&#xD;
      serum for neutralizing antibodies. These procedures will be repeated every four weeks until&#xD;
      the end of the study. Individuals with symptoms compatible will be followed-up to confirm&#xD;
      COVID-19 diagnosis as well as to assess severity, need for hospitalization and assisted&#xD;
      ventilation, sequels, and eventual reinfection. Levels of neutralizing antibodies and other&#xD;
      immune markers will be prospectively assessed in all infected participants, either&#xD;
      asymptomatic and symptomatic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of SARS-CoV-2 infection</measure>
    <time_frame>24 months</time_frame>
    <description>Number of cases with serological/virological diagnosis for SARS-Co-2 infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of COVID-19</measure>
    <time_frame>24 months</time_frame>
    <description>Number of cases of symptomatic SARS-CoV-2 infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalization due to COVID-19</measure>
    <time_frame>24 years</time_frame>
    <description>Number of cases of hospitalization due to symptomatic SARS-Co-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of neutralizing antibodies</measure>
    <time_frame>24 months</time_frame>
    <description>Level of neutralizing antibodies in participants with SARS-Co-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previous SARS-CoV-2 infection</measure>
    <time_frame>6 months</time_frame>
    <description>Positive serology for SARS-Co-2 infection at baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of SARS-CoV-2 reinfection</measure>
    <time_frame>24 months</time_frame>
    <description>Number of a new SARS-CoV-2 infection in an individual with a proven previous infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of COVID-19 cases requiring mechanical ventilation</measure>
    <time_frame>24 months</time_frame>
    <description>Number of COVID-19 cases requiring mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of deaths due to COVID-19</measure>
    <time_frame>24 months</time_frame>
    <description>Number of deaths due to COVID-19</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of sequels after COVID-19</measure>
    <time_frame>24 months</time_frame>
    <description>Number and description of sequels attributed to COVID-19</description>
  </other_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">4100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>0-9 years</arm_group_label>
    <description>Participants aging 0-9 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10-19 years</arm_group_label>
    <description>Participants aging 10-19 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20-29 years</arm_group_label>
    <description>Participants aging 20-29 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30-39 years</arm_group_label>
    <description>Participants aging 30-39 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40-49 years</arm_group_label>
    <description>Participants aging 40-49 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50-59 years</arm_group_label>
    <description>Participants aging 50-59 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60-69 years</arm_group_label>
    <description>Participants aging 60-69 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>70-79 tears</arm_group_label>
    <description>Participants aging 70-79 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80+ years</arm_group_label>
    <description>Participants aging 80 years or more</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The sample size will be equally distributed in ten different cities of Brazil. Then, each&#xD;
        site will have same representation of each age group. Participants can be selected from&#xD;
        other ongoing community-based studies conducted in the site and from community in general.&#xD;
        Balance of participant according to sex is recommended to the sites in all age group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any sex or age&#xD;
&#xD;
          -  Providing informed consent&#xD;
&#xD;
          -  Agreement with all study visits, procedure and contacts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous suspected or confirmed COVID-19&#xD;
&#xD;
          -  Febrile illness in the latest 72 hours&#xD;
&#xD;
          -  Olfactory or gustatory dysfunction in the last three months&#xD;
&#xD;
          -  Healthcare worker in a service with routine attention to COVID-19 patients&#xD;
&#xD;
          -  Any conditions that can might hurdle participant's compliance to the study in tha&#xD;
             opinion of the study team&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Butantan Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <phone>+55(11)26279300</phone>
    <email>ricardo.palacios@butantan.gov.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidade Federal do Ceará</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60430-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Castelo Branco Coelho, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ivo Castelo Branco Coelho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade de Brasília</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>71691-082</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Adolfo Sierra Romero, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gustavo Adolfo Sierra Romero, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30750-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro M Teixeira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mauro M Teixeira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Júlio Müller da Universidade Federal de Mato Grosso</name>
      <address>
        <city>Cuiabá</city>
        <state>Mount</state>
        <zip>78048-610</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cor J Fontes, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Cor J Fontes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Roraima - UFRR</name>
      <address>
        <city>Boa Vista</city>
        <state>Roraima</state>
        <zip>69304-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allex J da Fonseca, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Allex J da Fonseca, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas em Medicina Tropical de Rondônia (CEPEM)</name>
      <address>
        <city>Porto Velho</city>
        <state>RO</state>
        <zip>78918-791</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhelio B Pereira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dhelio B Pereira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Sergipe</name>
      <address>
        <city>Laranjeiras</city>
        <state>SE</state>
        <zip>49170-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Q Gurgel, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Q Gurgel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual de Serrana</name>
      <address>
        <city>Serrana</city>
        <state>SP</state>
        <zip>14150-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcos Borges, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marcos Borges, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>08270-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Messias Soares Filho, MD, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Samuel Messias Soares Filho, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina de São José do Rio Preto - FAMERP</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurício L Nogueira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Maurício L Nogueira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Evandro Chagas - Fiocruz</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21710-232</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Siqueira, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>André Siqueira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 infection</keyword>
  <keyword>Asymptomatic Infections</keyword>
  <keyword>Antibodies, Neutralizing</keyword>
  <keyword>Immunity, Humoral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

